In this episode of "Better Biopharma," host Tyler Menichiello is joined by Bonum Therapeutics' chief scientific officer, Diane Hollenbaugh, Ph.D., and chief business officer, Neela Patel, Ph.D. They talk about the inherent challenges of developing complex molecules like conditionally active biologics, sharing advice on CMC strategy, analytical methodology, and working with contract manufacturing and development partners. Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenic...
All content for Better Biopharma is the property of Tyler Menichiello and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode of "Better Biopharma," host Tyler Menichiello is joined by Bonum Therapeutics' chief scientific officer, Diane Hollenbaugh, Ph.D., and chief business officer, Neela Patel, Ph.D. They talk about the inherent challenges of developing complex molecules like conditionally active biologics, sharing advice on CMC strategy, analytical methodology, and working with contract manufacturing and development partners. Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenic...
Engineering Bacterial Vector-Based Immunotherapies With OS Therapies’ Paul Romness and Robert Petit, Ph.D.
Better Biopharma
36 minutes
1 month ago
Engineering Bacterial Vector-Based Immunotherapies With OS Therapies’ Paul Romness and Robert Petit, Ph.D.
In this episode of “Better Biopharma,” host Tyler Menichiello is joined by OS Therapies’ CEO, Paul Romness, and chief medical and scientific officer, Robert Petit, Ph.D. The three discuss the development and manufacturing of the company’s lead asset, OST-HER2, a Listeria-based immunotherapy for osteosarcoma. They also explain the unique CMC challenges around developing a safe bacterial vector. Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/ Keep up with everyt...
Better Biopharma
In this episode of "Better Biopharma," host Tyler Menichiello is joined by Bonum Therapeutics' chief scientific officer, Diane Hollenbaugh, Ph.D., and chief business officer, Neela Patel, Ph.D. They talk about the inherent challenges of developing complex molecules like conditionally active biologics, sharing advice on CMC strategy, analytical methodology, and working with contract manufacturing and development partners. Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenic...
